Entheon Biomedical: Looking to Remedy the Root Causes of Addiction

With an expert team of scientists and world-class advisors, Entheon Biomedical is looking to remedy the root causes of addiction. Additionally, The co …

Entheon Biomedical

Focused on Addiction

With an expert team of scientists and world-class advisors, Entheon Biomedical is looking to remedy the root causes of addiction. Additionally, The company is well funded and is currently in phase one of its clinical trials program.

The focus of Entheon is on addiction. They plan to combat it by developing a unique treatment system using DMT. Furthermore, it's well tolerated with few adverse effects - pure DMT is the ideal molecule for advancing and sustaining new models of psychedelic-assisted therapy. Through an assisted therapeutic experience, Entheon will allow patients to erase problematic neural pathways fueling addiction and mental illness. Thus facilitating the creation of new pathways towards recovery.

The Advancement of DMT

DMT has been used therapeutically for hundreds of years in the form of ayahuasca. Moreover, it has been scientifically studied since at least the 1950s. Likewise, it has been present throughout the plant kingdom and is safe in humans.

For more information on Entheon Biomedical Corp. (CSE: ENBI, OTCQB: ENTBF) please click the request investor info button.

You might also like

Ivan Bebek on Where the Biggest Mining Returns May Still Lie
Metals & Mining
March 4, 2026

Ivan Bebek on Where the Biggest Mining Returns May Still Lie

Veteran mining entrepreneur Ivan Bebek believes the current gold and silver cycle may only be getting started.

This is some text inside of a div block.
Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine
Health & Wellness
March 3, 2026

Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine

Advanced heart failure continues to rise globally, while the supply of donor hearts remains limited. This structural imbalance creates a significant and expanding market opportunity, with thousands of patients each year lacking viable treatment options and placing growing economic pressure on healthcare systems.

This is some text inside of a div block.
BMO ETFs Highlights Simplicity and Low Cost in Asset Allocation ETFs
ETFs
March 3, 2026

BMO ETFs Highlights Simplicity and Low Cost in Asset Allocation ETFs

In Canada, management fees for asset allocation ETFs can range from approximately 50 basis points down to 15 basis points.

This is some text inside of a div block.
Subscribe and receive the investor Info